Kodiak Sciences (KOD) has moved into focus after unveiling first time scientific results from its pivotal DAYBREAK Phase 3 trial and other late stage programs at the American Academy of Ophthalmology 2026 meeting.
The recent American Academy of Ophthalmology presentations arrived after a sharp re-rating in Kodiak Sciences, with a 30-day share price return of 167.11% and a year-to-date share price return of 238.66%. That move sits alongside a very large 3-year total shareholder return, while the 5-year total shareholder return remains down 22.26%. This signals strong recent momentum built on top of a still mixed longer history.
Scan beyond Kodiak Sciences and see how other late stage biotech stocks with fresh trial data stack up using our curated 20 high quality undiscovered gems.
Kodiak Sciences has already delivered a very sharp move, yet the late stage data story is still developing. Is most of the upside already in the rear view mirror, or does valuation still leave room ahead?
Most Popular Narrative: 4% Overvalued
The most followed narrative values Kodiak Sciences at $85 per share, slightly below the recent close at $88.12. This frames today’s rally as pricing in more than that scenario implies.
The Phase 3 DAYBREAK wet AMD data showing Zenkuda meeting primary endpoints with planned multi indication filing and a majority of patients on extended 24 week dosing intervals creates room for pricing and regimen mix that could lift average revenue per patient and support higher long term gross margins.
See why 0 investors see Kodiak Sciences as 4% overvalued.
Result: Fair Value of $85 (OVERVALUED)
Still, Kodiak Sciences faces clear tripwires, including the risk that upcoming Phase 3 readouts fall short or that fresh capital raises dilute existing shareholders.
Find out about the key risks to this Kodiak Sciences narrative.
Another View On Kodiak Sciences Valuation
The most popular narrative pegs Kodiak Sciences at $85 per share and calls the stock slightly overvalued at $88.12. A different lens tells a very different story. Our DCF model values KOD at $768.06, which is a very large gap above the current price and indicates that the shares are trading well below that future cash flow estimate. This raises a key question: is the stock trading at a modest premium to an $85 fair value, or at a wide discount to a more aggressive cash flow scenario?
Look into how the SWS DCF model arrives at its fair value.
Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Kodiak Sciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 32 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.
Next Steps
If this mix of enthusiasm and caution around Kodiak Sciences feels familiar, treat it as your prompt to move fast and test the thesis for yourself. You can do this using our balanced view of 3 key rewards and 4 important warning signs.
Looking for more investment ideas beyond Kodiak Sciences?
If you only stop at Kodiak Sciences, you risk missing other opportunities entirely. Give yourself options by lining up a few fresh ideas side by side.
- Target resilient compounding potential by scanning a curated set of 32 high quality undervalued stocks that combine quality fundamentals with discounted prices.
- Strengthen your downside protection by focusing on a list of solid balance sheet and fundamentals (25 results) that can better handle shocks and funding pressure.
- Get ahead of Wall Street by combing through 20 high quality undiscovered gems that pair strong financials with limited current attention.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com